Clinical trials: HIV Disease
HIV Infections
A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus
To evaluate the safety and effectiveness of Retrovir (AZT) when used as prophylaxis for health care workers at risk for HIV infection from exposure to HIV-contaminated blood or blood components.
- Trial name
- NCT00002287
- Testing
- Zidovudine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Glaxo Wellcome
Infection, Human Immunodeficiency Virus
Drug Interaction Study Between Dolutegravir and Prednisone
Dolutegravir (DTG, GSK1349572 is an integrase inhibitor that is currently in Phase 3 clinical development for the treatment of human immunodeficiency virus (HIV) infection.
- Trial name
- NCT01425099
- Testing
- Dolutegravir, Prednisone
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV
A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)
This study will evaluate HIV-1 RNA and the presence or absence of resistance at baseline and following seroconversion, assess the frequency of HIV-1 screening and screening method(s) used for evaluation of seroconverters, and…
- Trial name
- NCT01902472
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Gilead Sciences
HIV Infections
A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects
To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in…
- Trial name
- NCT00002428
- Testing
- HIV-1 Peptide Vaccine, Microparticulate Monovalent, rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical
HIV Infections
A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
To evaluate the efficacy of Saquinavir-SGC combination with Zidovudine and Lamivudine in the treatment of HIV-1 infected patients with no previous anti-retroviral drug therapy.
- Trial name
- NCT00002367
- Testing
- Saquinavir, Lamivudine, Zidovudine
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
HIV
Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.
A randomized, controlled, open-label, dose-exploration study to assess the effectiveness and safety of Lipovirtide combined with nucleoside drugs in HIV-infected patients who have not received antiviral treatment before.
- Trial name
- NCT06061536
- Testing
- Lipovirtide 10mg, Lipovirtide 40mg, Lipovirtide 60mg
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Shanxi Kangbao Biological Product Co., Ltd.
AIDS Dementia Complex, HIV Infections
Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy
The purpose of this study is to see if it is safe to give multiple doses of CPI-1189 to HIV-infected, otherwise healthy, males. The study will also look at how CPI-1189 affects the levels of HIV, T cells (cells in the body that…
- Trial name
- NCT00002209
- Testing
- CPI-1189
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Centaur Pharmaceuticals
HIV Infections
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on…
- Trial name
- NCT07650916
- Testing
- CAB ULA, RPV ULA, CAB LA
- Where
- 108 sites in United States, Argentina and 8 more
- Volunteers
- 564 people
- Sponsor
- ViiV Healthcare
HIV Infections
Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)
To investigate the potential benefit of providing passive immunity with hyperimmune anti-HIV human serum.
- Trial name
- NCT00002036
- Testing
- Anti-HIV Immune Serum Globulin (Human)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Abbott
HIV
TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.
The purpose of this study is to determine the antiviral activity, safety and tolerability of TMC114, formulated as an oral tablet, and administered with a low dose of ritonavir
- Trial name
- NCT00650832
- Testing
- TMC114; darunavir; Prezista
- Volunteers
- 334 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
The purpose of this study is to see if it is safe to give indinavir (IDV) and ritonavir (RTV) in combination with stavudine (d4T) and lamivudine (3TC) to HIV-positive patients who have never received anti-HIV therapy.
- Trial name
- NCT00002451
- Testing
- Indinavir sulfate, Ritonavir, Lamivudine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects
To evaluate an HIV lipopeptide immunotherapeutic, P3C541b, at two dose levels administered subcutaneously in HIV-seropositive patients.
- Trial name
- NCT00002353
- Testing
- P3C541b Lipopeptide
- Where
- United States
- Sponsor
- United Biomedical
HIV Infections
A Study of MKC-442 in Combination With Other Anti-HIV Drugs
The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.
- Trial name
- NCT00002412
- Testing
- Emivirine, Hydroxyurea, Stavudine
- Where
- United States
- Sponsor
- Triangle Pharmaceuticals
Pre-Exposure Prophylaxis of HIV Infection
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)
The goals of this clinical study are to learn more about the study drug lenacapavir (LEN), by comparing the consistent and continuous use of LEN and emtricitabine/tenofovir disoproxil fumarate (coformulated; Truvada®) (F/TDF)…
- Trial name
- PURPOSE 5 (NCT06513312)
- Testing
- Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
- Where
- 14 sites in France, United Kingdom
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
HIV, Sexually Transmitted Infections
Addressing Proven Factors in HIV Prevention for Latino Youth
This study tests the effectiveness of the bilingual Health and Success program, which aims to support Latino parents and schools in their efforts to promote the academic success and healthy choices of youth, with the goal of…
- Trial name
- NCT01633879
- Testing
- audio-CD parent education, health and success parent and school
- Volunteers
- 3,400 people, healthy volunteers welcome
- Sponsor
- Education Development Center, Inc.
HIV Infections
A Study of ddC in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Have Not Had Success With Zidovudine (AZT)
AMENDED: To provide ddC for patients with AIDS or advanced ARC who have failed treatment with, are intolerant to or are ineligible to receive zidovudine (AZT) and to demonstrate that ddC monotherapy is safe, and tolerable in this…
- Trial name
- NCT00002279
- Testing
- Zalcitabine
- Where
- United States
- Sponsor
- Hoffmann-La Roche
HIV Infection
An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.
The primary objective of the TMC114-C215 study is to evaluate the safety and tolerability of TMC114/RTV over time. The secondary objectives are to evaluate the antiviral activity over time and to evaluate the immunological effect…
- Trial name
- NCT00081588
- Testing
- TMC114
- Where
- 64 sites in United States, Argentina and 11 more
- Volunteers
- 555 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects
The purpose of this study is to compare the safety, tolerability and antiviral activity between once-daily (QD) and twice-daily (BID) dosing of lopinavir/ritonavir and to further characterize the pharmacokinetics of once-daily…
- Trial name
- NCT00043966
- Testing
- Lopinavir/ritonavir, Tenofovir DF, Emtricitabine
- Where
- 52 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- Abbott
HIV, AIDS
TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.
The purpose of this study is to investigate the pharmacokinetic interaction between the combination of ethinylestradiol and norethindrone and TMC278 25 mg once daily.
- Conditions
- HIV, AIDS, Oral Contraceptive
- Trial name
- NCT00739622
- Testing
- TMC278
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
The hypothesis tested in this study is that doravirine (MK-1439) at the final dose selected is superior to efavirenz, each given in combination with TRUVADA®, as measured by the percentage of participants with CNS events by Week…
- Trial name
- NCT01632345
- Testing
- Doravirine, Efavirenz, TRUVADA®
- Volunteers
- 342 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.